Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatment‐free survival analysis of the <scp>AICE</scp> trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatment‐free survival analysis of the AICE trial

Published:2022-11 Issue:S2 Volume:129 Page:32-39
ISSN:1470-0328
Container-title:BJOG: An International Journal of Obstetrics & Gynaecology
language:en
Short-container-title:BJOG

Author:

Xiang Libing¹,Shen Lina¹,Chen Yulian¹,Guo Yi²,Jiang Rong¹,Zhang Wen¹,Jia Huixun³,Wu Zhenyu²,Zang Rongyu¹

Affiliation:

1. Ovarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital Fudan University Shanghai China

2. Department of Biostatistics, School of Public Health Fudan University Shanghai China

3. Clinical Research Center, Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

Publisher

Wiley

Subject

Obstetrics and Gynecology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1471-0528.17326

Reference21 articles.

1. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

2. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

3. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer

4. Intraperitoneal antineoplastic drug delivery: rationale and results

5. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT);Journal of Gynecologic Oncology;2024

2. Supragastric lesser sac: an insidious site for surgical exploration during the debulking surgery in advanced ovarian cancer;Journal of Gynecologic Oncology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3